scout
Opinion|Videos|December 19, 2025

ASCENT-03 and ASCENT-04 Sacituzumab Govitecan Safety Data Shared at SABCS 2025

Updated safety from the ASCENT-03 and ASCENT-04 trials were shared at the 2025 San Antonio Breast Cancer Symposium (SABCS). Both studies explored sacituzumab govitecan in the first-line setting for patients with triple-negative breast cancer, with ASCENT-03 exploring the ADC as a monotherapy and ASCENT-04 evaluating the ADC in combination with the PD-1 inhibitor pembrolizumab. In this video, Laura Huppert, MD, highlights the safety outcomes from the trials presented at SABCS 2025 and shares her expertise on managing adverse events associated with these treatments.

Newsletter

Stay up to date on practice-changing data in community practice.


Latest CME